Author

Loris Riccardo Lopetuso

EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

Loris Riccardo Lopetuso  et al.

EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Loris Riccardo Lopetuso  et al.

IL-33 ACTIVATES CD73-EXPRESSING CELLS PROMOTING TUMORIGENESIS DURING COLITIS-ASSOCIATED COLORECTAL CANCER
IL-33 ACTIVATES CD73-EXPRESSING CELLS PROMOTING TUMORIGENESIS DURING COLITIS-ASSOCIATED COLORECTAL CANCER

Loris Riccardo Lopetuso  et al.

IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Loris Riccardo Lopetuso  et al.

TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY
TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY

Loris Riccardo Lopetuso  et al.

SARCOPENIA AND IBD: MOLECULAR AND MICROBIAL PATHWAYS AND POTENTIAL PHARMACOLOGICAL MODULATORS IN EXPERIMENTAL MODELS OF CHRONIC INFLAMMATORY BOWEL DISEASE
SARCOPENIA AND IBD: MOLECULAR AND MICROBIAL PATHWAYS AND POTENTIAL PHARMACOLOGICAL MODULATORS IN EXPERIMENTAL MODELS OF CHRONIC INFLAMMATORY BOWEL DISEASE

Loris Riccardo Lopetuso  et al.

THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY
THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY

Loris Riccardo Lopetuso  et al.

BASIC ULTRASOUND KNOWLEDGE AMONG YOUNG GASTROENTEROLOGISTS: AN ITALIAN SURVEY
BASIC ULTRASOUND KNOWLEDGE AMONG YOUNG GASTROENTEROLOGISTS: AN ITALIAN SURVEY

Loris Riccardo Lopetuso  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE

Loris Riccardo Lopetuso  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Loris Riccardo Lopetuso  et al.

IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMT-DERIVED MUCOSAL HEALING
IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMT-DERIVED MUCOSAL HEALING

Loris Riccardo Lopetuso  et al.

IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMT-DERIVED MUCOSAL HEALING
IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMT-DERIVED MUCOSAL HEALING

Loris Riccardo Lopetuso  et al.

HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE
HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE

Loris Riccardo Lopetuso  et al.

THE SOLUTE CARRIER LC22A4/OCTN1AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE
THE SOLUTE CARRIER LC22A4/OCTN1AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE

Loris Riccardo Lopetuso  et al.

THE SOLUTE TRANSPORTER OCTN1/SLC22A4 AFFECTS DISEASE SEVERITY AND RESPONSE TO INFLIXIMAB IN EXPERIMENTAL COLITIS: ROLE OF GUT MICROBIOTA AND IMMUNE MODULATION
THE SOLUTE TRANSPORTER OCTN1/SLC22A4 AFFECTS DISEASE SEVERITY AND RESPONSE TO INFLIXIMAB IN EXPERIMENTAL COLITIS: ROLE OF GUT MICROBIOTA AND IMMUNE MODULATION

Loris Riccardo Lopetuso  et al.

RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE
RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE

Loris Riccardo Lopetuso  et al.

SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION
SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION

Loris Riccardo Lopetuso  et al.

REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Loris Riccardo Lopetuso  et al.

ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS
ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS

Loris Riccardo Lopetuso  et al.

Item 1 - 20 / 20
1